NCT07352826 The Effect of Blood Carboxyhemoglobin Levels on NF-kB, NRF2 and PGC-1α During Low-flow and Normal-flow Anesthesia
| NCT ID | NCT07352826 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ataturk Training and Research Hospital |
| Condition | Anesthesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-02-20 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-02-20 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. However, the endogenous production of CO suggests that it may confer protective mechanisms to the host. These protective effects include inhibition of platelet activation, smooth muscle relaxation, vasoactive properties, anti-inflammatory and anti-apoptotic actions, and beneficial influences on neurotransmission. Despite its toxic potential, low-concentration endogenous CO may provide protection linked to the body's defense mechanisms. In this study, we aimed to investigate the anti-apoptotic effects of carbon monoxide at low concentrations. To this end, the relationships between COHb levels and plasma levels of NF-κB, NRF2, and PGC-1α were analyzed statistically.
Eligibility Criteria
Inclusion Criteria: aged 18-70 years classified as ASA I scheduled for inhalational anesthesia lasting ≥2 hours Exclusion Criteria: Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease pregnant or breastfeeding women trauma patients those undergoing emergency surgery procedures lasting \<2 hours those receiving intraoperative blood transfusion smokers individuals who decline participation
Frequently Asked Questions
Who can join the NCT07352826 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Anesthesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07352826 currently recruiting?
Yes, NCT07352826 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ataturk Training and Research Hospital to inquire about joining.
Where is the NCT07352826 trial being conducted?
This trial is being conducted at Erzurum, Turkey (Türkiye).
Who is sponsoring the NCT07352826 clinical trial?
NCT07352826 is sponsored by Ataturk Training and Research Hospital. The trial plans to enroll 120 participants.